The postoperative survival of colon cancer mainly refers to the prognosis, which has many correlations with disease stage, pathological histological condition, degree of surgical eradication and tumor site. Early stage colon cancer refers to stage I confined to mucosal tumor without lymph node metastasis, and the five-year survival rate can reach more than 90%, and five-year survival is the standard for medical science to judge the cure rate. For locally progressive stage II or stage III colon cancer, the five-year survival rate can reach 50%-78% after comprehensive treatment such as surgery and chemotherapy. For advanced patients with distant metastasis and recurrence, if they can be surgically resected radically after radiotherapy and chemotherapy, they can also have a better survival. For patients with extensive metastases, the survival of advanced patients is also significantly prolonged with the combination of targeted therapies such as bevacizumab, cetuximab and now PD-1 immunotherapy drugs on top of radiation and chemotherapy.